Join
Live feed
·
PRReleasevia Quantisnow
Zenas BioPharma Inc. logo

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress

ByQuantisnow·Wall Street's wire, on your screen.
ZBIO· Zenas BioPharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZBIO (Zenas BioPharma Inc.) and more on Quantisnow.